{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:07:00Z","timestamp":1787774820861,"version":"build-2784847793"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV, other sexually transmitted infections (STIs) and unintended pregnancies are critical and interlinked health risks for millions of women of reproductive age worldwide. Multipurpose prevention technologies (MPTs) offer an innovative approach for expanding combined pregnancy and\/or disease prevention. So far, MPT development efforts have focused mostly on HIV prevention, but about half of product candidates comprise compounds active against non-HIV STIs as well. This review aims to provide a framework that promotes the efficient advancement of the most promising preclinical products through the development pathway and into the hands of end-users, with a focus on women in low- and middle-income countries (L\/MICs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This mini review provides a summary of the current landscape of the MPT field. It comprises a landscape assessment of MPTs in development, complemented by a series of 28 in-depth, semi-structured key informant interviews (KIIs) with experts representing different L\/MIC perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results<\/jats:title>\n                    <jats:p>We identified six primary action strategies to advance MPTs for L\/MICs, including identification of key research gaps and priorities. For each action strategy, progress to date and key recommendations are included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To realize the life-saving potential of MPTs and maximize the momentum made to date, a strategic, collaborative and well-funded response to the gaps and next steps outlined in this paper is critical. A coordinated response can add rigor and efficiency to the development process, to successfully advance the most promising MPT products to the hands of end-users.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frph.2023.1150857","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:07:20Z","timestamp":1688357240000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries"],"prefix":"10.3389","volume":"5","author":[{"given":"Bethany","family":"Young Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Mike","family":"Chirenje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Isabelle","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherise","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen P\u00e9rez","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"B1","volume-title":"In danger: UNAIDS global AIDS update 2022","year":"2022"},{"key":"B2","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"key":"B4","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(22)00936-9","article-title":"Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"400","author":"Haakenstad","year":"2022","journal-title":"Lancet"},{"key":"B6","year":"2021"},{"key":"B7","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijpharm.2017.08.061","article-title":"Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro","volume":"531","author":"Tyo","year":"2017","journal-title":"Int J Pharm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0198478","DOI":"10.1371\/journal.pone.0198478","article-title":"Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides","volume":"13","author":"Tintori","year":"2018","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/biolre\/ioaa087","article-title":"Development of multipurpose technologies products for pregnancy and STI prevention: update on polyphenylene carboxymethylene MPT gel development\u2020","volume":"103","author":"Weitzel","year":"2020","journal-title":"Biol Reprod"},{"key":"B11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/biolre\/ioaa092","article-title":"Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders\u2020","volume":"103","author":"Hemmerling","year":"2020","journal-title":"Biol Reprod"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","article-title":"The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention","volume":"21","author":"van der Straten","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s10461-019-02715-1","article-title":"Efficacy is not everything: eliciting women\u2019s preferences for a vaginal HIV prevention product using a discrete-choice experiment","volume":"24","author":"Browne","year":"2020","journal-title":"AIDS Behav"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1007\/s10461-022-03713-6","article-title":"Couples\u2019 preferences for \u201c2 in 1\u201d multipurpose prevention technologies to prevent both HIV and pregnancy: results of a discrete choice experiment in Uganda and Zimbabwe","volume":"26","author":"Minnis","year":"2022","journal-title":"AIDS Behav"},{"key":"B15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/pharmaceutics11080374","article-title":"Topical inserts: a Versatile delivery form for HIV prevention","volume":"11","author":"Peet","year":"2019","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10461-019-02576-8","article-title":"Perspectives from young South African and Zimbabwean women on attributes of four (placebo) vaginal microbicide delivery forms","volume":"24","author":"Weinrib","year":"2020","journal-title":"AIDS Behav"},{"key":"B17","year":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"113849","DOI":"10.1016\/j.addr.2021.113849","article-title":"Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention","volume":"176","author":"Krovi","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1927477","DOI":"10.1080\/26410397.2021.1927477","article-title":"Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa","volume":"29","author":"Minnis","year":"2021","journal-title":"Sex Reprod Health Matters"},{"key":"B20","year":"2014"},{"key":"B21","author":"Minnis","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1966656","article-title":"Fertility reduction and the quality of family planning services","volume":"20","author":"Jain","year":"1989","journal-title":"Stud Fam Plann"},{"key":"B23","author":"Gray","year":"2006"},{"key":"B24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/GRF.0000000000000070","article-title":"The contraceptive CHOICE project round up: what we did and what we learned","volume":"57","author":"McNicholas","year":"2014","journal-title":"Clin Obstet Gynecol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e25872","DOI":"10.1002\/jia2.25872","article-title":"HIV prevention: better choice for better coverage","volume":"25","author":"Bekker","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IJWH.S185712","article-title":"\u201cWe are not the same\u201d: African women\u2019s view of multipurpose prevention products in the TRIO clinical study","volume":"11","author":"Shapley-Quinn","year":"2019","journal-title":"Int J Womens Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/apc.2017.0075","article-title":"Favoring \u201cpeace of mind\u201d: a qualitative study of African women\u2019s HIV prevention product formulation preferences from the MTN-020\/ASPIRE trial","volume":"31","author":"van der Straten","year":"2017","journal-title":"AIDS Patient Care STDs"},{"key":"B28","year":"2021"},{"key":"B29","year":"2022"},{"key":"B30","year":"2019"},{"key":"B31","year":"2022"},{"key":"B32","author":"Robles","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0253-7184.156680","article-title":"Antibiotic resistance in prevalent bacterial and protozoan sexually transmitted infections","volume":"36","author":"Krupp","year":"2015","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"B34","author":"Landovitz","year":"2020"},{"key":"B35","year":"2021"},{"key":"B36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/biolre\/ioaa085","article-title":"Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women\u2020","volume":"103","author":"Young Holt","year":"2020","journal-title":"Biol Reprod"},{"key":"B37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.contraception.2017.08.014","article-title":"Perfect use and typical use pearl index of a contraceptive mobile app","volume":"96","author":"Scherwizl","year":"2017","journal-title":"Contraception"},{"key":"B38","year":"2011"},{"key":"B39","year":""},{"key":"B40","year":""},{"key":"B41","year":""},{"key":"B42","year":""},{"key":"B43","year":""},{"key":"B44","year":""},{"key":"B45","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10461-022-03658-w","article-title":"HIV pre-exposure prophylaxis implant stated preferences and priorities: results of a discrete choice experiment among women and adolescent girls in Gauteng province, South Africa","volume":"26","author":"Little","year":"2022","journal-title":"AIDS Behav"},{"key":"B46","author":"Quaife","year":"2016"},{"key":"B47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-pharmtox-010818-021625","article-title":"Surviving in the valley of death: opportunities and challenges in translating academic drug discoveries","volume":"59","author":"Parrish","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B48","year":"2020"},{"key":"B49","year":"2019"},{"key":"B50","year":"2021"},{"key":"B51","author":"Bershtyn","year":"2023"},{"key":"B52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.9745\/GHSP-D-19-00383","article-title":"Scaling up access to implants: a summative evaluation of the implants access program","volume":"8","author":"Braun","year":"2020","journal-title":"Glob Health Sci Pract"},{"key":"B53","year":"2022"},{"key":"B54","year":"2007"},{"key":"B55","year":"2022"},{"key":"B56","year":"2022"},{"key":"B57","year":"2022"},{"key":"B58","year":"2022"},{"key":"B59","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(19)31387-X","article-title":"How should we listen to ECHO?","volume":"394","author":"Noguchi","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2023.1150857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:07:24Z","timestamp":1688357244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2023.1150857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":59,"alternative-id":["10.3389\/frph.2023.1150857"],"URL":"https:\/\/doi.org\/10.3389\/frph.2023.1150857","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"article-number":"1150857"}}